EyeRelax 2 EyeCare Device

About EyeRelax2

EyeRelax2 is an International Award winning eye care device clinically programmed to improve eyesight, effective for both myopia and presbyopia commonly known as near and far sightedness. It is developed based on European studies on visual fields and bio-spectrum technology.

Our ciliary muscles tense up when we focus on near objects. Our ciliary muscles relax we focus on distance objects.

Prolonged near sighted activities cause our ciliary muscles to go into spasm, resulting to transient myopia. EyeRelax2 relieves mechanical strain inhibit myopia progression through myopic defocus, the ciliary muscles is also relieved from spasm therefore regaining its usual focusing ability.

The ciliary muscles weaken when one grows old (usually >40 years old), resulting in the development of presbyopia (farsightedness). EyeRelax2 is effective top strengthen the focusing function, thereby delaying adult presbyopia.

Principles of EyeRelax2

It is based on the expansive clinical research on myopia that EyeRelax2 is developed. Primarily EyeRelax2 seeks to relieve mechanical strain with accommodation training and inhibit myopia progression through myopic defocus. Based on the study of visual fields, EyeRelax2 enhances the retina activity to further inhibit myopia progression.

In each 8 minutes sequence, EyeRelax2 is clinically programmed to:

- improve accommodation accuracy and dynamics visual near-far simulation for accommodative facility training;
- Impose myopic defocus with accommodation cue to inhibit myopia progression;
- produce specific visual spectrum producing rich images in contrast, spatial content, color, luminance and stereo;
• produce isoluminant chromatic (color patterns) and achromatic (black-white) images with based on the characteristics of our visual receptors and synapses to improve retina activity; and
• visual - audio synchronization to enhance concentration of subject to maximize VEP.

Electrical Supplies

By treating both the accommodative system and the visual neuro system, with imposed myopic defocus, EyeRelax2 is hence the most complete device in its prevention of myopia and improvement to our eyesight.

Studies Supporting the Efficacy of EyeRelax2 for Myopia Treatment

A recent study in Malaysia National University of Malaysia (UKM) in 2006/07 to evaluate the efficacy of EyeRelax2 in reducing and controlling myopia progression arrived at the following conclusions:

<table>
<thead>
<tr>
<th>Date</th>
<th>September 2006 to March 2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>21 subjects with 39 eyes with myopia from range -0.25DS to -1.00DS, mean age 22.36 years old</td>
</tr>
<tr>
<td></td>
<td>14 subjects with 28 eyes with myopia from range &gt;-1.00DS to -3.00DS, mean age 21.43 years old</td>
</tr>
</tbody>
</table>

Results for myopia group with myopia from range -0.25DS to -1.00DS after 90 days of treatment

• Significant changes in visual acuity measurement with wearing glasses (p=0.043)
• Significant changes in the degree of myopia with wearing glasses (p=0.00)

Results for myopia group with myopia from range >-1.00DS to -3.00DS after 90 days of treatment

A study in China XiAn Hospital of Children's Squint and Lazy Eye in 2000 to evaluate the efficacy of EyeRelax2 for myopia and amblyopia arrived at the following conclusions:

<table>
<thead>
<tr>
<th>Date</th>
<th>March 2000 to August 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>35 amblyopic subjects (60 eyes) and 19 pseudo myopic subjects (38 eyes)</td>
</tr>
</tbody>
</table>

Age Group:

Amblyopic: 82% of the subjects are aged 3 to 8, and 18% of the subjects were aged 9 to 12 years old.

Myopic: Subjects are aged 10 to 22 years old

Results for pseudo myopic group after 60 days of treatment
• 37 shortsighted eyes recovered from pseudo myopia
• 1 shortsighted eye had no improvement to its vision.

Results for amblyopic group after 60 days of treatment
• 52% or 31 amblyopic eyes recovered with naked vision of at least 1.0
• 35% or 21 amblyopic eyes vision improved by 2 lines on the eye-chart
• 13% or 8 amblyopic eyes had no improvement to their vision

A study in China's Xi'An Municipal No. 4 Hospital in 1999 to evaluate the efficacy of EyeRelax2 for myopia and amblyopia arrived at the following conclusions:

Date: February 1999 to August 1999

Population: 74 amblyopic subjects (102 eyes) and 17 pseudo myopic subjects (34 eyes)

Age Group: 82% of the subjects are aged 3 to 8, and 18% of the subjects were aged 9 to 12 years old.

Results for pseudo myopic group after 90 days of treatment
• 30 shortsighted eyes recovered from pseudo myopia
• 4 shortsighted eyes vision improved by 2 lines on the eye-chart

Results for amblyopic group after 90 days of treatment
• 53% or 54 amblyopic eyes recovered with naked vision of up to 0.9
• 39% or 40 amblyopic eyes vision improved by 2 lines on the eye-chart
• 8% or 8 amblyopic eyes had no improvement to their vision

More Principles of EyeRelax2
EyeRelax2 Amblyopia device seeks the efficiency of the above from knowledge accumulated in the field of neuroscience, especially in the area of visual fields.

Human retina exist 3 types of cones cells that are sensitive to different light spectrum, that is 570 -590 nm (red), 530 - 565 nm (green) and 430 - 460 nm (blue) respectively. In addition there are rods cells that are sensitive to grey contrast. These are light sensitive cells.

Beyond the rods and cones cells, we have bipolar and ganglion cells that helps to transmit signals generated by the rod and con cells to our brains. These cells exhibit very different individual reactions to visible spectrum.

One type of ganglion cells for example is excited by spectrum of 620 - 680 nm (red) but is inhibited by spectrum of 530 - 565 nm (green). The second type of ganglion cell presents the
reverse characteristic. The third type of ganglion cell is excited by 430 - 460 nm spectrum (blue) but it inhibited by 570 - 590 nm spectrum (yellow); and again the fourth type exhibits the reverse characteristics. Research studies reveal that when compared to stationary image or constant spectrum alone, the visual receptive field reaction is strongest when exposed to significant spectrum contrast; varying spectrum contrast; darkness/brightness contrast; and stereo image contrast.

EyeRelax2 Amblyopia device is clinically programmed based on the findings of these researches to generate high response from our retina rods cells, cones cells, the ganglion cells, thereby heightening the visual evoked potential to our vision neuro. In the 10 minutes programming sequencing, EyeRelax2 is designed to:

- produce specific visual spectrum producing rich images in contrast, spatial content, color, luminance and stereo;
- produce isoluminant chromatic (color patterns) and achromatic (black-white) images with based on the characteristics of our visual receptors and synapses to improve retina activity; excite the cones cells with red, blue & green spectrum;
- excite the rods cells at the same time with blinking lights;
- excite the bipolar and ganglion cells with clinically sequencing red, blue, green & yellow spectrum aiming to achieve heightened activities; and
- visual - audio synchronization to enhance concentration of subject to maximize VEP.

EyeRelax2 Amblyopia is a safe, and very easy to use. Just 10 minutes for each treatment, three times daily together with the existing prescription by your ophthalmologist. EyeRelax2 Amblyopia is most effective device for amblyopia treatment.

**Studies Supporting the Efficacy of EyeRelax2 for Amblyopia Treatment**

In April 2005, Dr Liu Chun Ming of Shenzhen Eye Hospital released an extract of his study at China's 11th National Congress of Strabismus and Pediatric Ophthalmology. In his extract, he noted that treatment of amblyopic eyes with patching alone takes about 10.6 months to recover. Comparatively, treatment with patching and EyeRelax2 reduces the recover time to only 6.4 months.

A study in China's Xi'An Hospital of Children's Squint and Lazy Eye in 2000 to evaluate the efficacy of EyeRelax2 for myopia and amblyopia arrived at the following conclusions:

<table>
<thead>
<tr>
<th>Date</th>
<th>March 2000 to August 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>35 amblyopic subjects (60 eyes) and 19 pseudo myopic subjects (38 eyes)</td>
</tr>
<tr>
<td>Age Group</td>
<td>Amblyopic : 82% of the subjects are aged 3 to 8, and 18% of the subjects were aged 9 to 12 years old.</td>
</tr>
</tbody>
</table>
Myopic: Subjects are aged 10 to 22 years old

Results for pseudo myopic group after 60 days of treatment
- 37 shortsighted eyes recovered from pseudo myopia
- 1 shortsighted eye had no improvement to its vision.

Results for amblyopic group after 60 days of treatment
- 52% or 31 amblyopic eyes recovered with naked vision of at least 1.0
- 35% or 21 amblyopic eyes vision improved by 2 lines on the eye-chart
- 13% or 8 amblyopic eyes had no improvement to their vision

A study in China's Xi'an Municipal No. 4 Hospital in 1999 to evaluate the efficacy of EyeRelax2 for myopia and amblyopia arrived at the following conclusions:

**Date:** February 1999 to August 1999

**Population:** 74 amblyopic subjects (102 eyes) and 17 pseudo myopic subjects (34 eyes)

**Age Group:** 82% of the subjects are aged 3 to 8, and 18% of the subjects were aged 9 to 12 years old.

Results for pseudo myopic group after 90 days of treatment
- 30 shortsighted eyes recovered from pseudo myopia
- 4 shortsighted eyes vision improved by 2 lines on the eye-chart

Results for amblyopic group after 90 days of treatment
- 53% or 54 amblyopic eyes recovered with naked vision of up to 0.9
- 39% or 40 amblyopic eyes vision improved by 2 lines on the eye-chart
- 8% or 8 amblyopic eyes had no improvement to their vision

EyeRelax2 Award
- Gold Medal Award (International Invention Expo)
- Watson's Health and Beauty 2008 (Best Innovative EyeCare Device)
- Creative Medal Award (International Invention Expo)
More